News Buzz – ACI Worldwide Inc (NASDAQ:ACIW), Workday Inc (NYSE:WDAY), Nature’s Sunshine Prod. (NASDAQ:NATR), Ophthotech Corp (NASDAQ:OPHT)

ACI Worldwide (NASDAQ:ACIW) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a report issued on Monday. The firm currently has a $59.10 price target on the stock. Zacks‘s price objective would indicate a potential upside of 5.54% from the stock’s previous close. ACI Worldwide Inc (NASDAQ:ACIW) stock performance was 1.03% in last session and finished the day at $18.55. Traded volume was 342,404.00million shares in the last session and the average volume of the stock remained 677.89K shares. The beta of the stock remained 1.04. ACI Worldwide Inc (NASDAQ:ACIW) insider ownership is 1.70%.

Workday Inc (NASDAQ:WDAY) VP James P. Shaughnessy unloaded 8,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $90.98, for a total transaction of $727,840.00. Following the completion of the transaction, the vice president now directly owns 59,709 shares of the company’s stock, valued at approximately $5,432,325. Workday Inc (NYSE:WDAY) rose 1.41 percent to $81.52 Monday on volume of 896,705.00million shares. The intra-day range of the stock was $80.30 to $82.49. Workday Inc (NYSE:WDAY) has a market capitalization of $22.37billion.

On June 26, 2014, Nature’s Sunshine Products, Inc. (NASDAQ:NATR) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, a company organized in the People’s Republic of China (“Fosun Pharma”) entered into (i) a Stock Purchase Agreement (the “Stock Purchase Agreement”), (ii) a Stockholder Agreement (the “Stockholder Agreement”), and (iii) a Standstill Agreement (the “Standstill Agreement”). On June 26, 2014, the Company, Fosun Industrial Co., Limited (a wholly-owned subsidiary of Fosun Pharma, “Fosun Industrial”) and Nature’s Sunshine Hong Kong Limited (“NSP HK”) entered into a Share Subscription Agreement (the “Subscription Agreement”). Nature’s Sunshine Prod. (NASDAQ:NATR)’s stock on July 14, 2014 reported a decrease of -0.18% to the closing price of $16.31. Its fifty two weeks range is $12.91 -$20.15. The total market capitalization recorded $263.88million. The overall volume in the last trading session was 22,023.00million shares. In its share capital, NATR has 16.19million outstanding shares.

Oppenheimer initiated Ophthotech Corp (NASDAQ:OPHT) with a Outperform and price target of $95 (the note is dated July 7); they expect Ophthotech’s PDGF inhibitor Fovista being developed for wet AMD to succeed in an ongoing Phase 3 program (data 2016), with FDA approval to follow in 2017. Their view is based on solid proof-of-concept from randomized Phase 2 data that showed clear benefits in combination with an approved VEGF inhibitor (standard of care). On Monday, shares of Ophthotech Corp (NASDAQ:OPHT) dropped -1.81% to close the day at $40.60. Company monthly performance is recorded as -8.78%. Ophthotech Corp NASDAQ:OPHT) quarterly revenue growth is 30.71%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone